A well-established firm closing in on a decade in business and recently (2023) in receipt of substantial VC funding, Abilita Bio is a biotechnology company - an alumni of JLabs San Diego - addressing enabling discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) and ion channels, including G Protein Coupled Receptors (GPCRs) and ion channels. A privately held, innovation-driven biotechnology company focused on discovering and developing therapeutic antibodies targeting the most challenging and medically important multi-span membrane proteins. Abilita Bios validated drug discovery engine builds on the foundation of its powerful EMP target evolution platform and deep membrane protein expertise to a suite of internal antibody discovery technologies.The firm has established research collaborations with global pharmaceutical companies to advance their internal drug discovery programs targeting GPCRs and ion channels and continues to extend the EMP platform into new applications through multiple risk-sharing collaborations with biotechnology industry partners, while leveraging the EMP platform to fuel a robust internal drug discovery pipeline focused on treating cancer and chronic
